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Artery reopening is required for the 
neurorestorative effects of angiotensin 
modulation after experimental stroke
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Abstract 
Background: Blood flow restoration with fibrinolysis and thrombectomy is recommended to limit injury in stroke 
patients with proximal artery occlusion. Angiotensin receptor blockers have been shown to be neuroprotective in 
models of permanent and temporary occlusion, but the benefits on expression of trophic factors have been seen only 
when the artery is reopened. It is possible that early artery opening with endovascular intervention may increase the 
likelihood of identifying an effective combination therapy for patients.
Methods: Normotensive male Wistar rats were subjected to mechanical middle cerebral artery occlusion (either 
temporary or permanent), followed by randomization to receive candesartan (0.3 mg/kg IV) or saline. Functional 
outcome, infarct size, and biochemical changes were assessed 24 h after ischemia induction.
Results: Lack of reperfusion blunted candesartan induced neuroprotection (p < 0.05) and reduced the improve-
ment of functional outcome (p < 0.05). With reperfusion, candesartan increased mature BDNF expression in the 
contralateral hemisphere (p < 0.05) and activated prosurvival (Akt-GSK3-β) signaling (p < 0.05). Without reperfusion, 
candesartan significantly reduced VEGF expression and MMP activation and increased NOGO A expression, creating 
an environment hostile to recovery.
Conclusion: Candesartan induced pro-recovery effects are dependent on the presence of reperfusion.
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Background
Stroke is an acute neurologic disease and a leading cause 
of morbidity and mortality [1]. In the majority of cases, 
stroke results from a mechanical occlusion of one of the 
intracranial arteries [1]. This results in reduced cerebral 
blood flow below a threshold necessary for neuronal 
function resulting in neurologic dysfunction [2, 3]. Re-
establishing blood flow to the ischemic area is essential 
to salvage metabolically stunted tissue [4, 5]. In fact, the 
only FDA approved drug for the acute management of 
stroke, alteplase, is intended to restore blood flow to the 
affected region [5]. Despite its effectiveness, the use of 
alteplase is limited by a 4.5 h time window and a long list 
of contraindications [5].
Endovascular thrombectomy offers a new potential 
to restore cerebral perfusion [6–10]. Data from recent 
clinical trials demonstrated the safety and efficacy of 
thrombectomy with a stent retriever in the management 
of stroke [6–10]. The beneficial effect was observed even 
when the intervention was performed up to 12 h after the 
onset of the stroke [9]. In addition to restoring cerebral 
perfusion, opening an occluded artery is expected to 
theoretically improve drug delivery to the affected brain 
region. This might enhance the neuroprotective and pro-
recovery effects of pharmaceutical agents. Although the-
oretically plausible, it is still unknown whether opening 
occluded arteries would impact the neuroprotective and 
pro-recovery effects of pharmaceutical agents.
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Angiotensin receptor blockers (ARBs) have been shown 
to reduce the extent of neuronal damage and improve 
outcome after experimental cerebral ischemia [11–19]. 
ARB-induced neurovascular protective and pro-recovery 
effects were found to be mediated through a number of 
mechanisms including cerebral blood flow restoration, 
antinflammatory, and antioxidant effects [11, 14, 15, 
20–23]. Data from our lab showed the ability of ARBs to 
induce a proangiogenic effect after stroke [12, 18] and 
we subsequently implicated an increased expression of 
growth factors after stroke in their pro-recovery effects 
[12, 18, 24, 25]. Although ARB-induced neuroprotection 
has been observed in studies with reperfusion compo-
nent as well as in permanent occlusion studies [11, 12, 
14, 15, 20, 22], it is still unknown whether the neuropro-
tective effects of ARBs are modulated by the presence of 
reperfusion in a direct head to head comparison. In this 
investigation, our aim was to assess whether reperfusion 
modulates candesartan induced pro-recovery effects.
Methods
Animals
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the 
Charlie Norwood Veterans Affairs Medical Center (09-
04-008). Male Wistar rats (280–300 g) were subjected to 
middle cerebral artery occlusion (MCAO) as described 
earlier [16, 18]. Briefly, the ventral side of the neck was 
shaved and probed with iodine and 70  % ethanol. A 
midline incision was made to expose neck blood ves-
sels. The common carotid artery (CCA) and the external 
carotid artery (ECA) were isolated. After being isolated, 
the ECA was ligated, cauterized and a small incision 
was introduced in the ECA stub. A silicone coated fila-
ment was then introduced into the internal carotid artery 
(ICA) through the ECA stub and was pushed all the way 
to block the origin of the middle cerebral artery (MCA). 
After 3 h of occlusion, animals either underwent reperfu-
sion by withdrawal of the filament or remained perma-
nently occluded. At the same time, these animals were 
randomized to receive either candesartan (0.3  mg/kg) 
or saline. Animals were followed up for 24 h after occlu-
sion when they were sacrificed by decapitation. In one 
set of animals, brains were harvested, sliced and stained 
with 5 % Triphenyl Tetrazolium Chloride (TTC) to assess 
infarct size and edema volume. In another set of animals, 
brains were harvested and flash frozen in liquid nitrogen 
for biochemical analysis.
Behavioral outcome
Behavioral outcome was evaluated 24  h after MCAO 
using the modified Bederson score as described previ-
ously [16].
Protein quantification
Brains were homogenized using 1X RIPA buffer sup-
plemented with protease inhibitor cocktail, PMSF, and 
sodium orthovanidate. Protein content was determined 
using bicinchonic acid (BCA) method (Thermo-Scien-
tific) and 30 μg proteins from each samples were loaded 
and separated on 4–20 % ready-made criterion gel (Bio-
Rad). Proteins were transferred to nitrocellulose mem-
branes and membranes were blocked with 5  % low fat 
milk in TBST (1  % tween in Tris-Buffered Saline). The 
membranes were probed with antiBDNF (1:250; Santa 
Cruz biotechnologies; Santa Cruz, CA, USA), TrkB 
(1:500, abcam; Cambridge, MA, USA), pGSK3-β (1:1000, 
Cell Signaling; Danvers, MA, USA), total GSK3-β (1:1000, 
Cell Signaling; Danvers, MA, USA), pAkt-473(1:1000, 
Cell Signaling; Danvers, MA, USA), pan Akt (1:1000, Cell 
Signaling; Danvers, MA, USA). Expression was quanti-
fied by measuring the optic density of the band relative to 
its cognate actin band using image J software.
VEGF quantification was performed using enzyme-
linked immunosorbent assay kit (RayBiotech, Norcross, 
GA, USA) according to the manufacturer protocol. 
Briefly, brain homogenates (100 μl) were incubated over-
night on antibody coated plate. Wells were washed and 
then incubated with a biotinylated secondary antibody 
then TMB substrate was added and spectrophotomet-
ric analysis was done. Signal was measured at 450  nm 
(BioTek, Winooski, VT, USA).
MMP zymography
MMP zymography was performed as described in Kozak 
et  al. [18]. Briefly, brain homogenates were electropho-
retically separated on an acrylamide gel containing gela-
tin. Gelatinolytic activity was quantified by densitometric 
analysis (Gel-Pro v 3.1; Media Cybernetics, Carlsbad, 
Calif ).
Statistical analysis
Statistical significance was determined using student 
t test and two way ANOVA as appropriate. Statistical 
analyses were performed using GraphPad prism software 
(5.1). p < 0.05 was considered significant.
Results
Candesartan induces neuroprotection and improves 
functional outcome
Data from our lab and others have demonstrated the 
neuroprotective effect of candesartan at hypotensive 
doses in normotensive or hypertensive animals [11, 14, 
18]. Accordingly, our interest shifted to assess whether 
sub-hypotensive doses of candesartan might induce a 
similar response in normotensive animals. To achieve 
this we used a dose of candesartan (0.3  mg/kg IV) that 
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was demonstrated to have a minimal effect on blood 
pressure (BP) when administered at reperfusion [25]. In 
this study, candesartan 0.3 mg/kg reduced infarct size by 
23 % (Fig. 1A) and improved the functional outcome as 
measured by modified Bederson score (Fig. 1B).
Reperfusion is essential for ARB‑induced neuroprotection 
but not for improving early functional outcome
Despite being essential for salvaging neurons in the 
penumbra, reperfusion has also been shown to cause 
additional injury to the ischemic tissue [26, 27]. Our previ-
ous data demonstrated the effects of candesartan admin-
istered at the time of reperfusion on stroke outcome [12, 
17]. In this investigation, we aimed at assessing whether 
reperfusion is necessary for candesartan induced neuro-
protection and functional outcome improvement. Lack of 
reperfusion blunted candesartan induced neuroprotec-
tion (Fig.  2A), but candesartan induced improvement in 
functional outcome at 24 h was maintained (Fig. 1B).
Candesartan modulates the expression of BDNF in a 
reperfusion dependent manner
BDNF has been shown to improve stroke outcome [28–
31] and we showed that candesartan up-regulates BDNF 
expression in both Wistar and hypertensive (SHR) rats, 
with [25] and without stroke [24]. We then set out to 
determine whether reperfusion was necessary for this 
effect. After temporary MCAO, candesartan significantly 
increased mature BDNF in the contralateral hemisphere 
of candesartan treated animals as compared to the ipsi-
lateral hemisphere (Fig.  2A). This increase in mature 
BDNF was accompanied by an increase in the mature to 
proBDNF ratio (Fig. 2C). In contrast to its effect in rep-
erfused animals, candesartan reduced mature BDNF in 
both hemispheres of non-reperfused animals (Fig.  2A). 
Candesartan also reduced the expression of proBDNF 
levels in the brain (Fig. 2B). Candesartan did not alter the 
levels of proBDNF in reperfused animals (Fig. 2B).
Candesartan modulates the expression of TrkB in a 
reperfusion dependent manner
BDNF induced neuroprotection is mediated through 
TrkB signaling [32, 33]. In reperfused brains, candesartan 
did not alter the expression of TrkB after stroke (Fig. 2D). 
Interestingly, candesartan administration significantly 
reduced TrkB expression in the absence of reperfusion 
(Fig. 2D).
Candesartan up‑regulates the pro‑survival, Akt‑GSK3‑β 
axis
Recently, Guo et  al. [13] demonstrated the involvement 
of Akt-GSK3-β activity in BDNF mediated neuroprotec-
tion conferred by endothelial cells. Previously, our data 
suggested the involvement of GSK3-β in candesartan 
induced up-regulation of BDNF expression in endothelial 
cells [24]. Candesartan administration significantly acti-
vated the Akt-GSK3-β axis in both ipsilateral and con-
tralateral hemispheres (Fig. 3A, B, respectively).
Fig. 1 Reperfusion is essential for candesartan induced functional outcome improvement. Sub-hypotensive dose of candesartan conferred neuro-
protective effect after stroke in a reperfusion dependent manner (A). In addition, the ability of candesartan to improve functional outcome is also 
reperfusion dependent (B). *p < 0.05, a, b pairs of means with different letters are significantly different from each other. n = 8–14 per group
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Candesartan induced activation of Akt‑GSK3‑β signaling is 
reperfusion dependent
Similar to our findings on candesartan induced neuro-
protection, the activity of Akt-GSK3-β was reperfusion 
dependent. Lack of reperfusion blunted candesartan 
induced activation of Akt signaling (Fig. 3A) and GSK-3β 
inhibition (Fig. 3B).
Candesartan reduced VEGF expression in non‑reperfused 
brain after stroke
Data from our lab indicated the ability of candesartan 
to increase VEGF expression at both hypotensive [18] 
and sub-hypotensive doses [25]. These results were all 
derived from animals exposed to ischemia and reperfu-
sion. It was unknown whether this effect of candesartan 
is reperfusion dependent. Accordingly, we quantified 
VEGF expression in non-reperfused animals. Candesar-
tan treatment significantly reduced VEGF expression as 
compared to non-reperfused animals (Fig. 4B).
Candesartan reduced MMP activity in non‑reperfused 
animals after stroke
Kozak et  al. [18] reported that candesartan induced 
prorecovery effect was associated with an increase in 
MMP activity in reperfused animals. It was unknown 
whether this effect is reperfusion dependent or not, 
however. Without reperfusion, candesartan administra-
tion had the opposite effect and significantly reduced 
both MMP2 (Fig. 4C) and MMP9 (Fig. 4D) activity after 
stroke.
Candesartan increases Nogo‑A expression 
in non‑reperfused brain after stroke
To determine whether the observed effects of candesar-
tan on prorecovery mediators in non-reperfused brain 
are due to an overall reduced protein expression, the 
expression of Nogo-A, a neurite outgrowth inhibitor, 
was quantified. Candesartan increased the expression of 
Nogo-A expression in non-reperfused brain (Fig. 4A).
Fig. 2 Reperfusion modulates the ability of candesartan to affect the expression of BDNF/TrkB system components. Candesartan increased mature 
BDNF expression in the contralateral hemisphere in a reperfusion dependent manner (A). The effect of reperfusion is most prominent in proBDNF 
(B), BDNF/proBDNF ratio (C), and TrkB (D) expression. Groups connected by line are significantly different from each other. a,b pairs of means with 
different letters are significantly different from each other. n = 4 per group
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Fig. 3 Reperfusion is necessary for candesartan induced activation of survival signaling and ER stress amelioration. Candesartan induced neuro-
protection involves the activation of Akt (A) and GSK3-β signaling (B). Lack of reperfusion blunts the ability of candesartan to activate intracellular 
survival signals. Groups connected by line are significantly different from each other. a,b pairs of means with different letters are significantly different 
from each other. n = 4 per group
Fig. 4 Candesartan increases the expression of Nogo-A, and reduced VEGF and MMPs activity in non-reperfused brains. Candesartan administra-
tion in animals exposed to permanent middle cerebral artery occlusion increased Nogo-A expression in both hemispheres (A). Candesartan admin-
istration significantly reduced VEGF expression (B) and MMP2 and 9 activities (C and D, respectively). Groups connected by line are significantly 
different from each other. A, B pairs of means with different letters are significantly different from each other. n = 4 per group
Page 6 of 7Alhusban et al. Exp & Trans Stroke Med  (2016) 8:4 
Discussion
Our results demonstrate, for the first time, the essential 
requirement of reperfusion for the full neurorestorative 
effects of candesartan. Our results demonstrate both 
neuroprotective and pro-recovery effects of candesartan, 
when administered at a dose of 0.3 mg/kg. Previously, we 
demonstrated a neuroprotective and pro-recovery effect 
of candesartan in normal and hypertensive rats [12, 16–
19, 25] and at low and higher doses [25]. In a model of 
temporary cerebral ischemia, a single dose of candesar-
tan administered at the time of reperfusion resulted in a 
prolonged pro-recovery effect [18]. This effect was asso-
ciated with an increase in VEGF expression and MMP 
activity. In a follow-up study using the same dose, Guan 
et  al. [17] demonstrated a reduction in infarct size in 
non-reperfused animals, but no effect of candesartan on 
VEGF expression, or MMP activity. These contradictory 
findings suggest a possible reperfusion dependence in 
some aspects of candesartan induced pro-recovery effect 
after stroke. We now demonstrate a stark contrast in the 
expression of pro-recovery mediators after candesartan 
in reperfused and non-reperfused animals. Accordingly, 
our data provides the first direct evidence that supports 
the notion raised by the others that candesartan induced 
neuroprotection and pro-recovery effect is reperfusion 
dependent.
Consistent with these findings, candesartan induced 
upregulation of mature BDNF levels was completely 
reversed in non reperfused brain. Mature BDNF con-
tent in the brain is determined by both de novo expres-
sion and ProBDNF processing into the mature form 
[33]. Our results suggest that in non-reperfused brain, 
AT1 blockade reduces de novo expression of BDNF as 
detected by a reduction in both pro and mature forms of 
BDNF. Similarly, candesartan significantly reduced the 
expression TrkB in non-reperfused brain. These find-
ings are also consistently demonstrated in the activity of 
Akt-GSK-3β signaling axis which has been demonstrated 
to be involved in neuroprotection and improving func-
tional outcome after stroke [13]. In reperfused brains, 
candesartan administration significantly increased Akt 
and GSK3-β phosphorylation. In contrast, candesartan 
administration in permanent stroke model significantly 
reduced Akt and GSK3-β activity.
A plausible explanation of these interesting findings 
is suggested by studies on penumbra development and 
cellular bioenergetics after ischemia. In an elegant work 
Mies et al. [34] reported a 55 ml/100 gm/min threshold 
for protein synthesis in the brain. Below this threshold, 
protein synthesis in the brain ceases. To account for this 
possibility, our interest shifted to quantify the expres-
sion of proteins known to be involved in worsening 
stroke outcome. One candidate protein in this setting is 
Nogo-A, which has been shown to worsen stroke out-
come and to antagonize the effects of BDNF in neurons 
[35, 36]. If the observed reduction in BDNF and TrkB 
expression is due to stunted transcriptional machinery 
in non reperfused brain, Nogo-A expression would also 
be reduced. Interestingly, candesartan administration 
induced a robust increase in Nogo-A expression in non 
reperfused brain. Additionally, candesartan significantly 
reduced both VEGF expression and MMP2 and 9 in non 
reperfused brains. This finding suggests that candesartan 
induced reduction in BDNF and TrkB expression is not 
due to a mere synthetic machinery failure induced by a 
long duration of ischemia. In contrast, it suggests that 
lack of reperfusion reduces the expression or the bioa-
vailability of essential mediators for candesartan induced 
neurorestoration. This finding may help explain the 
conflicting results of the ACCESS [37] and SCAST [38] 
clinical trials with regard to candesartan’s effect on stroke 
outcome, where reperfusion was not assured.
In conclusion, our results demonstrate a reperfusion 
dependent candesartan induced improved stroke out-
come at sub-hypotensive doses. This neuroprotective and 
pro-recovery effect is mediated through an up-regulation 
of BDNF expression and the resulting activation of Akt-
GSK3-β signaling.
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